Clinical outcomes of PD patients having bilateral STN DBS using high-field interventional MR-imaging for lead placement

Jill L Ostrem, Nicholas B Galifianakis, Leslie C Markun, Jamie K Grace, Alastair J Martin, Philip A Starr, Paul S Larson, Jill L Ostrem, Nicholas B Galifianakis, Leslie C Markun, Jamie K Grace, Alastair J Martin, Philip A Starr, Paul S Larson

Abstract

Objective: Recently, an iMRI-guided technique for implanting DBS electrodes without MER was developed at our center. Here we report the clinical outcomes of PD patients undergoing STN DBS surgery using this surgical approach.

Methods: Consecutive PD patients undergoing bilateral STN DBS using this method were prospectively studied. Severity of PD was determined using the UPDRS scores, Hoehn and Yahr staging score, stand-sit-walk testing, and the dyskinesia rating scale. The primary outcome measure was the change in UPDRS III off medication score at 6 months. DBS stimulation parameters, adverse events, levodopa equivalent daily dose (LEDD), and DBS lead locations were also recorded. Seventeen advanced PD patients (9M/8F) were enrolled from 2007 to 2009.

Results: The mean UPDRS III off medication score improved from 44.5 to 22.5 (49.4%) at 6 months (p=0.001). Other secondary outcome measures (UPDRS II, III on medication, and IV) significantly improved as well (p<0.01). LEDD decreased by an average of 24.7% (p=0.003). Average stimulation parameters were: 2.9V, 66.4μs, 154Hz.

Conclusion: This pilot study demonstrates that STN DBS leads placed using the iMRI-guided method results in significantly improved outcomes in PD symptoms, and these outcomes are similar to what has been reported using traditional frame-based, MER-guided stereotactic methods.

Conflict of interest statement

conflicts of interest

The other authors have no financial disclosures.

Copyright © 2012 Elsevier B.V. All rights reserved.

Figures

Figure 1. Results of iMRI STN DBS…
Figure 1. Results of iMRI STN DBS on UPDRS Scores (n=14)
UPDRS – Unified Parkinson’s Disease Rating Scale raw score on X-axis. The Wilcoxon signed-rank test was significant compared to baseline for UPDRS II, III on medications, and IV (p

Source: PubMed

3
購読する